# A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

> **NCT01412060** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 765 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cariprazine

## Key facts

- **NCT ID:** NCT01412060
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-27
- **Primary completion:** 2014-09-03
- **Final completion:** 2014-09-03
- **Target enrollment:** 765 (ACTUAL)
- **Last updated:** 2018-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412060, "A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01412060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*